{"id":"conbercept-fixed","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"conjunctival hemorrhage"},{"rate":"10-20%","effect":"eye pain"},{"rate":"10-20%","effect":"conjunctival hyperemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Conbercept works by binding to vascular endothelial growth factor (VEGF) and preventing it from interacting with its receptors on the surface of endothelial cells, thereby inhibiting angiogenesis. This mechanism of action is thought to be responsible for its anti-tumor and anti-angiogenic effects.","oneSentence":"Conbercept is a recombinant human VEGF decoy receptor that inhibits angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:24.123Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diabetic macular edema"}]},"trialDetails":[{"nctId":"NCT05728476","phase":"NA","title":"Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema","status":"RECRUITING","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2024-03-05","conditions":"Diabetic Macular Edema, Pars Plana Vitrectomy, Conbercept","enrollment":102},{"nctId":"NCT01809223","phase":"PHASE3","title":"A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2012-08","conditions":"Choroid Neovascularization Secondary to Degenerative Myopia","enrollment":176}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"conbercept, Fixed","genericName":"conbercept, Fixed","companyName":"Chengdu Kanghong Biotech Co., Ltd.","companyId":"chengdu-kanghong-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Conbercept is a recombinant human VEGF decoy receptor that inhibits angiogenesis. Used for Diabetic macular edema.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}